Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phenomix withdraws IPO registration and signs deal with Forest

This article was originally published in Scrip

Executive Summary

Phenomix Corporation is withdrawing an IPO registration filed with the US Securities and Exchange Commission in January as a result of tough market conditions (ScripOnline, February 2nd, 2008). Meanwhile, it says it is to develop and commercialise its proprietary DDP-4 inhibitor dutogliptin (PHX1149), in Phase III trials for type 2 diabetes, with Forest Laboratories. Forest will pay Phenomix $75 million up front and the two companies will develop and commercialise the product in the US and will equally share profits and expenses. Phenomix could receive up to $340 million in up-front and milestone payments for the successful development and commercialisation of dutogliptin in the US. Upon commercialisation, they will co-promote the product there. Phenomix will promote the drug to endocrinologists and diabetologists and Forest to primary care and specialists. Forest has exclusive rights to develop and commercialise dutogliptin in Canada and Mexico, for which Phenomix will receive a royalty on sales in exchange for the rights to use jointly funded trial data in those countries. Phenomix retains development and commercialisation rights to the product outside North America, and will pay Forest a royalty on net sales. The composition-of-matter patent covering dutogliptin runs until 2024 and is subject to extension.

You may also be interested in...



Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel